CTOs on the Move

Global Research Services

www.grs-cro.com

 
Global Research Services is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.grs-cro.com
  • 2101 Gaither Rd Ste 450
    Rockville, MD USA 20850
  • Phone: 301.424.9700

Executives

Name Title Contact Details

Similar Companies

Longs Drug Stores of SC Inc

Longs Drug Stores of SC Inc is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cerevel

Cerevel Therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). The company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders, including Parkinson`s, Alzheimer`s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.

Anne Arundel Dermatology

With modern, attractive clinical offices in Annapolis, Glen Burnie, Hagerstown, Prince Frederick, Leonardtown, Kent Island, and Easton, 19 board certified physicians, 7 physician assistants, 2 certified nurse practitioners, a full service cosmetic lase...

X4 Pharmaceuticals

X4 Pharmaceuticals (Nasdaq: XFOR) is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancers. The company`s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4`s most advanced product candidate, mavorixafor (X4P-001), is in a global Phase 3 pivotal trial in patients with WHIM syndrome, a rare, inherited, primary immunodeficiency disease, and is currently also under investigation in combination with axitinib in the Phase 2a portion of an open-label Phase 1/2 clinical trial in clear cell renal cell carcinoma (ccRCC). X4 is also planning to commence clinical trials of mavorixafor in Severe Congenital Neutropenia (SCN) and Waldenström`s macroglobulinemia (WM) in 2019. The company was founded and is led by a team with extensive biopharmaceutical product development and commercialization expertise and is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options. X4 is a global company that is headquartered in Cambridge, Massachusetts with research offices based in Vienna, Austria.